Should You Buy LataMed AI Corp. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, LataMed AI Corp. (LMED) scores 4.2/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $0.06, our multi-model valuation analyzes whether the market has already discounted these weaknesses.
The short answer: 0 of 2 CirclFi valuation models project upside for LataMed AI Corp. (LMED) at $0.06 — the model consensus leans bearish, with a Quality Score of 4.2/10 and Value-Trap risk of 36/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for LataMed AI Corp. (LMED) in 2026?
What Is the Bull Case vs the Bear Case for LataMed AI Corp. (LMED)?
| Bull case | Bear case — $0.00 target (-98.5%) |
|---|---|
| No active model projects meaningful upside for LMED at $0.06. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. | According to the CirclFi Quality of Company (QOC) framework, LataMed AI Corp.'s score of 4.2/10 signals fundamental weaknesses that could undermine the investment thesis. |
| According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $0.00 (-98.5%), suggesting that the market price embeds overly optimistic growth assumptions. | |
| Industry headwind: technology obsolescence represents a meaningful risk for LataMed AI Corp. and its Software - Application peers. |
How Does LMED Compare to Its Software - Application Peers?
Valuation data pages: PARA · GDLG · LIVG · BLIV · ILLR · OCTV · DCBO · MNDY · BZAI · ADSK · PTC
Which Other Stocks Score Like LMED on Quality?
Closest companies to LMED’s Quality of Company score of 4.2/10, across all industries.
- ANVI — Anvi Global Holdings, Inc. (QOC 4.2) · analysis
- DSS — DSS, Inc. (QOC 4.2) · analysis
- APVO — Aptevo Therapeutics Inc. (QOC 4.2) · analysis
- NSTM — NovelStem International Corp. (QOC 4.2) · analysis
- MEDS — DataMEDS AI, Inc. (QOC 4.2) · analysis
- CPWR — Ocean Thermal Energy Corporation (QOC 4.2) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Software - Application Screens Does LMED Appear In?
So Is LataMed AI Corp. (LMED) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on LataMed AI Corp. at $0.06. 2/2 models flag overvaluation, median fair value sits at $0.01 (-87.6%), and the risk-reward profile appears unfavorable. Quality at 4.2/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. LataMed AI Corp.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About LMED Stock?
Should I buy LMED stock right now?
Based on CirclFi's multi-model analysis, 0 of 2 models see upside for LMED at $0.06. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in LataMed AI Corp.?
Key risks include: a below-average Quality Score of 4.2/10, indicating fundamental weakness; limited model coverage (2/13 active), reducing analytical confidence; wide model disagreement (1402% spread), signaling high uncertainty; general market and sector-specific risks affecting Software - Application companies. Always diversify and consult a financial advisor.
How does LMED compare to its competitors?
Among Software - Application peers, LMED holds a Quality Score of 4.2/10. Comparable companies include PARA (QOC 4.3), GDLG (QOC 4.1), LIVG (QOC 4.3). The relative ranking helps investors identify whether LMED offers better fundamental quality than alternatives in the same sector.
Is LMED a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. LMED's Quality Score of 4.2/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.
What price should I buy LMED at?
CirclFi does not provide target buy prices or price alerts. However, our 2 active models produce fair value estimates ranging from $0.00 to $0.01. At $0.06, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for LMED.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad